Prostatype Genomics FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Prostatype Genomics (PROGEN.ST) as of Oct 13, 2026 is 54.06 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 128.07 % — a change of -57.79% (lower).
Get this data via API
Financial Data API
FCF Conversion
54.06 %
YoY
-57.79%
Last updated:
The Prostatype Genomics FCF Conversion history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Conversion | YoY |
|---|---|---|
| 54.06 % | -57.79% | |
| 128.07 % | +40.75% | |
| 90.99 % | -4.43% | |
| 95.21 % | -19.90% | |
| 118.86 % | +40.40% | |
| 84.66 % | -43.88% | |
| 150.86 % | +35.54% | |
| 111.30 % | -45.30% | |
| 203.47 % | — |
Prostatype Genomics Stock analysis
Frequently Asked Questions about Prostatype Genomics stock
FCF Conversion Rate (FCF/EBITDA) of Prostatype Genomics is 54.06 % in 2025.
FCF Conversion Rate (FCF/EBITDA) of Prostatype Genomics changed from 128.07 % to 54.06 %, representing a -57.79% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.
FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.
A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Prostatype Genomics with sector peers and the industry average to assess whether it is attractive.
To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).
Cash Flow — Prostatype Genomics
All Key Metrics — Prostatype Genomics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth